Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2022-05-25 Annual Report
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Pacific Edge LTD FY22 Result 89 pages 5.2MB
Annual Report Classification · 95% confidence The document is a detailed announcement of audited financial results for the year ended 31 March 2022 by Pacific Edge. It includes comprehensive financial data such as revenue, net loss, operating expenses, cash flow, and capital raising details. It also discusses operational highlights, regional performance, investment initiatives, and outlook. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial analysis. The presence of audited financial results for a full fiscal year and detailed commentary aligns with the characteristics of an Annual Report (10-K) rather than a brief earnings release or a report publication announcement. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2022-05-25 English
Director Nomination Closing Date
Board/Management Information Classification · 95% confidence The document is a short announcement dated 23 May 2022 from Pacific Edge Limited regarding the closing date for director nominations ahead of its Annual Shareholder Meeting scheduled for 28 July 2022. It mentions the upcoming AGM and the process for director nominations but does not contain any financial data, detailed meeting materials, or voting results. It is not a full report or presentation but an announcement related to board/management changes (director nominations). Therefore, the document fits best under Board/Management Information (MANG). The document length is short (1146 characters), consistent with an announcement rather than a full report.
2022-05-23 English
Director Nomination Closing Date 1 page 249.4KB
Board/Management Information Classification · 95% confidence The document is a brief announcement regarding the closing date for director nominations ahead of the company's Annual Shareholder Meeting (AGM). It mentions the upcoming AGM date and details about the nomination process but does not include any meeting materials, voting results, or financial data. The document length is short (1146 characters), and it serves as a notification rather than a report or detailed presentation. Therefore, it fits best under Board/Management Information (MANG) as it relates to changes or nominations in the company's board of directors.
2022-05-22 English
Advancing Cxbladder as standard of care – Clinical Study
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 10th May 2022 from Pacific Edge Limited. It discusses the initiation and details of a clinical study called LOBSTER to advance the Cxbladder Monitor as a standard of care for bladder cancer surveillance. The content focuses on the study design, patient enrollment, clinical utility, and expected outcomes. There are no financial statements, earnings data, regulatory certifications, or voting results. The document is informational about a clinical trial and company progress rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the study and company plans, not just a notice of report availability. The document fits best as a Regulatory Filing (RNS) because it is a general company announcement about clinical study progress and does not fit into any other specific category such as earnings release, capital update, or management information.
2022-05-10 English
Clinical Study Advancing Cxbladder as standard of care 3 pages 696.3KB
Regulatory Filings Classification · 90% confidence The document is a detailed announcement about a clinical trial study (LOBSTER) related to the Cxbladder Monitor for bladder cancer surveillance. It describes the study design, objectives, patient enrollment, and expected outcomes. There is no indication that this is a financial report, earnings release, regulatory filing, or any other corporate filing type. The content is focused on clinical trial progress and medical research rather than financial or corporate governance matters. It does not fit into any of the specific financial or corporate filing categories such as Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content, the best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2022-05-09 English
Pacific Edge Full Year Result to be Announced 26 May 2022
Report Publication Announcement Classification · 95% confidence The document is a company announcement dated 3 May 2022 from Pacific Edge Limited. It announces the upcoming release date of the full year results for the fiscal year ending 31 March 2022, scheduled for 26 May 2022. It also provides details about an investor and analyst conference call/webcast to discuss these results. The document does not contain any actual financial data or detailed report content; it is merely an announcement of the forthcoming full year results and the related investor event. The document length is 4174 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, announcements about the timing and release of reports without the report itself should be classified as Report Publication Announcement (RPA).
2022-05-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.